Literature DB >> 31934041

Clinical significance of USP7 and EZH2 in predicting prognosis of laryngeal squamous cell carcinoma and their possible functional mechanism.

Ming-Jie Zhang1, De-Shang Chen1, Hui Li1, Wei-Wei Liu1, Guo-Ying Han1, Yue-Feng Han1.   

Abstract

BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is one of the most prevalent cancer types in the world. The ubiquitin specific protease 7 (USP7), a kind of deubiquitylating enzyme, has been reported to play multifaceted roles in different tumor types. EZH2 has been found to be highly expressed in various malignantcells and high expression of EZH2 is closely related to tumor growth infiltration, lymph node involvement, clinical stage, and poor prognosis. The aim of this study was to investigate the expression and function of USP7 and EZH2 in LSCC. CASE
PRESENTATION: Immunohistochemical staining and histochemical staining were performed to explore the expression of USP7 and EZH2 in both LSCC tissues and adjacent normal laryngeal tissues. Chi-square test, univariate analysis, and multivariate analysis were conducted to statistically evaluate the clinical significance of USP7 and EZH2.
CONCLUSIONS: USP7and EZH2 affects LSCC evolution; USP7 and EZH2 were upregulated in LSCC tissues, which can serve as independent prognostic predictors, and potential therapeutic targets for LSCC. IJCEP
Copyright © 2019.

Entities:  

Keywords:  EZH2; Laryngeal squamous cell carcinoma; USP7; lymphatic invasion

Year:  2019        PMID: 31934041

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  6 in total

1.  Full methylation of H3K27 by PRC2 is dispensable for initial embryoid body formation but required to maintain differentiated cell identity.

Authors:  Sara A Miller; Manashree Damle; Jongmin Kim; Robert E Kingston
Journal:  Development       Date:  2021-04-15       Impact factor: 6.868

2.  CircRNA CORO1C Regulates miR-654-3p/USP7 Axis to Mediate Laryngeal Squamous Cell Carcinoma Progression.

Authors:  Jianbin Zhang; He Li; Jiangping Li; Saixiong Ke
Journal:  Biochem Genet       Date:  2022-01-22       Impact factor: 2.220

3.  Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer.

Authors:  Katharina Leitner; Irina Tsibulak; Verena Wieser; Katharina Knoll; Daniel Reimer; Christian Marth; Heidi Fiegl; Alain G Zeimet
Journal:  Sci Rep       Date:  2020-11-23       Impact factor: 4.379

4.  Polycomb and Trithorax Group Proteins: The Long Road from Mutations in Drosophila to Use in Medicine.

Authors:  D A Chetverina; D V Lomaev; M M Erokhin
Journal:  Acta Naturae       Date:  2020 Oct-Dec       Impact factor: 1.845

Review 5.  Post-translational modifications of EZH2 in cancer.

Authors:  Zhongwei Li; Minle Li; Diandian Wang; Pingfu Hou; Xintian Chen; Sufang Chu; Dafei Chai; Junnian Zheng; Jin Bai
Journal:  Cell Biosci       Date:  2020-12-11       Impact factor: 7.133

Review 6.  Deubiquitinating Enzymes Orchestrate the Cancer Stem Cell-Immunosuppressive Niche Dialogue: New Perspectives and Therapeutic Potential.

Authors:  Jun-Nan Guo; Bai-Rong Xia; Shen-Hui Deng; Chang Yang; Ya-Nan Pi; Bin-Bin Cui; Wei-Lin Jin
Journal:  Front Cell Dev Biol       Date:  2021-06-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.